These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 16006135)

  • 1. Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment.
    Zala D; Benchoua A; Brouillet E; Perrin V; Gaillard MC; Zurn AD; Aebischer P; Déglon N
    Neurobiol Dis; 2005 Dec; 20(3):785-98. PubMed ID: 16006135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenovirus vector-based in vitro neuronal cell model for Huntington's disease with human disease-like differential aggregation and degeneration.
    Dong X; Zong S; Witting A; Lindenberg KS; Kochanek S; Huang B
    J Gene Med; 2012 Jul; 14(7):468-81. PubMed ID: 22700462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotection by Hsp104 and Hsp27 in lentiviral-based rat models of Huntington's disease.
    Perrin V; Régulier E; Abbas-Terki T; Hassig R; Brouillet E; Aebischer P; Luthi-Carter R; Déglon N
    Mol Ther; 2007 May; 15(5):903-11. PubMed ID: 17375066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length.
    de Almeida LP; Ross CA; Zala D; Aebischer P; Déglon N
    J Neurosci; 2002 May; 22(9):3473-83. PubMed ID: 11978824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early and reversible neuropathology induced by tetracycline-regulated lentiviral overexpression of mutant huntingtin in rat striatum.
    Régulier E; Trottier Y; Perrin V; Aebischer P; Déglon N
    Hum Mol Genet; 2003 Nov; 12(21):2827-36. PubMed ID: 12952868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into huntington's disease molecular pathogenesis.
    Miller J; Arrasate M; Shaby BA; Mitra S; Masliah E; Finkbeiner S
    J Neurosci; 2010 Aug; 30(31):10541-50. PubMed ID: 20685997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High efficiency adenovirus-mediated expression of truncated N-terminal huntingtin fragment (htt552) in primary rat astrocytes.
    Wang L; Lin F; Wu J; Qin Z
    Acta Biochim Biophys Sin (Shanghai); 2009 Apr; 41(4):325-34. PubMed ID: 19352548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inducing huntingtin inclusion formation in primary neuronal cell culture and in vivo by high-capacity adenoviral vectors expressing truncated and full-length huntingtin with polyglutamine expansion.
    Huang B; Schiefer J; Sass C; Kosinski CM; Kochanek S
    J Gene Med; 2008 Mar; 10(3):269-79. PubMed ID: 18067195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice.
    Li H; Li SH; Yu ZX; Shelbourne P; Li XJ
    J Neurosci; 2001 Nov; 21(21):8473-81. PubMed ID: 11606636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a rat model of Huntington's disease based on targeted expression of mutant huntingtin in the forebrain using adeno-associated viral vectors.
    Gabery S; Sajjad MU; Hult S; Soylu R; Kirik D; Petersén Å
    Eur J Neurosci; 2012 Sep; 36(6):2789-800. PubMed ID: 22731249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin.
    Benchoua A; Trioulier Y; Zala D; Gaillard MC; Lefort N; Dufour N; Saudou F; Elalouf JM; Hirsch E; Hantraye P; Déglon N; Brouillet E
    Mol Biol Cell; 2006 Apr; 17(4):1652-63. PubMed ID: 16452635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term lentiviral-mediated expression of ciliary neurotrophic factor in the striatum of Huntington's disease transgenic mice.
    Zala D; Bensadoun JC; Pereira de Almeida L; Leavitt BR; Gutekunst CA; Aebischer P; Hayden MR; Déglon N
    Exp Neurol; 2004 Jan; 185(1):26-35. PubMed ID: 14697316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease.
    McBride JL; Ramaswamy S; Gasmi M; Bartus RT; Herzog CD; Brandon EP; Zhou L; Pitzer MR; Berry-Kravis EM; Kordower JH
    Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9345-50. PubMed ID: 16751280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-dependent neuroprotection of VEGF₁₆₅ in Huntington's disease striatum.
    Ellison SM; Trabalza A; Tisato V; Pazarentzos E; Lee S; Papadaki V; Goniotaki D; Morgan S; Mirzaei N; Mazarakis ND
    Mol Ther; 2013 Oct; 21(10):1862-75. PubMed ID: 23799534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular and subcellular localization of Huntingtin [corrected] aggregates in the brain of a rat transgenic for Huntington disease.
    Petrasch-Parwez E; Nguyen HP; Löbbecke-Schumacher M; Habbes HW; Wieczorek S; Riess O; Andres KH; Dermietzel R; Von Hörsten S
    J Comp Neurol; 2007 Apr; 501(5):716-30. PubMed ID: 17299753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease.
    Hermel E; Gafni J; Propp SS; Leavitt BR; Wellington CL; Young JE; Hackam AS; Logvinova AV; Peel AL; Chen SF; Hook V; Singaraja R; Krajewski S; Goldsmith PC; Ellerby HM; Hayden MR; Bredesen DE; Ellerby LM
    Cell Death Differ; 2004 Apr; 11(4):424-38. PubMed ID: 14713958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. R6/2 neurons with intranuclear inclusions survive for prolonged periods in the brains of chimeric mice.
    Reiner A; Del Mar N; Deng YP; Meade CA; Sun Z; Goldowitz D
    J Comp Neurol; 2007 Dec; 505(6):603-29. PubMed ID: 17948889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of mutated huntingtin fragment in the putamen is sufficient to produce abnormal movement in non-human primates.
    Palfi S; Brouillet E; Jarraya B; Bloch J; Jan C; Shin M; Condé F; Li XJ; Aebischer P; Hantraye P; Déglon N
    Mol Ther; 2007 Aug; 15(8):1444-51. PubMed ID: 17505477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A role of mitochondrial complex II defects in genetic models of Huntington's disease expressing N-terminal fragments of mutant huntingtin.
    Damiano M; Diguet E; Malgorn C; D'Aurelio M; Galvan L; Petit F; Benhaim L; Guillermier M; Houitte D; Dufour N; Hantraye P; Canals JM; Alberch J; Delzescaux T; Déglon N; Beal MF; Brouillet E
    Hum Mol Genet; 2013 Oct; 22(19):3869-82. PubMed ID: 23720495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons.
    Chang DT; Rintoul GL; Pandipati S; Reynolds IJ
    Neurobiol Dis; 2006 May; 22(2):388-400. PubMed ID: 16473015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.